GYS32661 is currently developed as an anticancer agent, essentially positioned to treat breast and colon cancers [125], but this potent Rac1 inhibitor could be envisioned for the treatment of other malignancies associated with an overactivation of Rac1, such as bladder cancers. Here, RAC1 is linked to urinary bladder cancer.